Brandon L Probst

Title: The Innovative Contributions of Brandon L Probst

Introduction

Brandon L Probst is a notable inventor based in Wylie, Texas, recognized for his significant contributions to the field of biotechnology. With a focus on epigenetic modifications, his work has the potential to impact cancer treatment and therapeutic strategies.

Latest Patents

Brandon holds a patent titled "Epigenetic modifications at TNFα as biomarkers for sensitivity to Smac mimetic-induced apoptosis." This invention provides a method for determining the sensitivity of a cell population to apoptosis induced by Smac mimetics, either as a single agent or in combination with other chemotherapeutic drugs. The method involves assaying for an epigenetic modification at the TNFα locus in the cell population, comparing it to a cell population that is not sensitive to such apoptosis. The presence of this epigenetic modification indicates that the cell population is sensitive to apoptosis induced by Smac mimetics.

Career Highlights

Brandon is currently employed at Joyant Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work at the company focuses on innovative approaches to enhance cancer therapies and improve patient outcomes.

Collaborations

Brandon collaborates with Lai Wang, contributing to the collective expertise and research initiatives at Joyant Pharmaceuticals, Inc. Their partnership exemplifies the importance of teamwork in driving scientific advancements.

Conclusion

Brandon L Probst's innovative work in epigenetics and cancer therapy showcases his dedication to improving medical treatments. His patent and ongoing research at Joyant Pharmaceuticals, Inc. highlight his role as a key contributor to the field.